Skip to content

Laparoscopic Sleeve Gastrectomy: a Cohort Study

The Effect of Residual Gastric Antrum Size During Laparoscopic Sleeve Gastrectomy in Reducing Postoperative Gastrointestinal Symptoms: a Cohort Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03629808
Enrollment
138
Registered
2018-08-14
Start date
2018-07-10
Completion date
2020-04-20
Last updated
2020-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Laparoscopic Sleeve Gastrectomy

Keywords

metabolic surgery, laparoscopic sleeve gastrectomy

Brief summary

This is a prospective cohort study, which subjects were obese patients requiring LSG surgery. LSG with different gastric resection starting points (2-4cm/4-6 cm from pylorus) as intervention method. The main observation is the incidence and extent of upper gastrointestinal symptoms (such as nausea, vomiting, retching, reflux, difficulty swallowing, etc.).In addition, secondary observations include the excess weight loss (%EWL) and postoperative complications. Aim to investigate the effects of LSG surgery in different starting points of gastric resection on postoperative upper gastrointestinal symptoms.

Interventions

PROCEDURE4-6cm from starting point of gastrectomy to pylorus

The starting point of gastrectomy of the distance from the pylorus is 4-6cm during operative.

PROCEDURE2-4cm from starting point of gastrectomy to pylorus

The starting point of gastrectomy of the distance from the pylorus is 2-4cm during operative.

Sponsors

Peking Union Medical College Hospital
CollaboratorOTHER
Beijing Tiantan Hospital
CollaboratorOTHER
Beijing Hospital
CollaboratorOTHER_GOV
Beijing Shijitan Hospital, Capital Medical University
CollaboratorOTHER
Beijing Friendship Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
15 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Patients were accepted for surgery if they satisfied the guidelines of the Society of Chinese Gastroenterological Surgeons \[body mass index (BMI) ≥40 kg/m2 or BMI ≥35 kg/m2 with at least one co-morbidity associated with obesity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea), age between 18 and 60 years, and failure of conservative treatment over 2 years\]. * All patients undergo preoperative upper gastrointestinal (GI) endoscopy.

Exclusion criteria

* any patient who had previously been submitted to any type of bariatric surgery; * patient currently taking anti-nausea or GERD medications preoperatively; * any current smokers; * active duodenal/gastric ulcer disease; * difficult to treat gastroesophageal reflux disease (GERD) with a large hiatal hernia; * previous major gastrointestinal surgery; * diagnosed or suspected malignancy; * poorly controlled significant medical or psychiatric disorders; * disorders such as a medical history of major pathology; * can not be able to understand and willing to participate in this registry with signature.

Design outcomes

Primary

MeasureTime frameDescription
The incidence rate of upper gastrointestinal symptoms after surgery1 year after surgeryWe use three scales to evaluate the incidence of upper gastrointestinal symptoms,include the Chinese translation of R-INVR(the Index of Nausea, Vomiting, and Retching)、EAT-10(Validity and Reliability of the Eating Assessment Tool) and GIS(GERD impact serve).These three scales describe postoperative upper gastrointestinal symptoms,which include vomiting, dysphagia,and acid reflux,heartburn.We focus on the incidence rate of the above symptoms in one year after surgery during 1 year. Visit: Post-op 12 months Visit(±7 Days)

Secondary

MeasureTime frameDescription
The excess weight loss (%EWL) after surgery1 year after surgeryPercent excess weight loss (%EWL), %EWL=\[(initial weight)-(post-op weight)\]/\[(initial weight)-(ideal weight)\] (in which ideal weight is defined by the weight corresponding to a BMI of 25 kg/m2). Visit 1: Baseline Visit (Day 0-1) Visit 2: Post-op 3 days Visit Visit 3: Post-op 7 days Visit Visit 4: Post-op 1 month Visit(±3 Days) Visit 5: Post-op 3 months Visit(±7 Days) Visit 6: Post-op 12 months Visit(±7 Days)
the rate of postoperative complications after surgery1 year after surgeryPostoperative complications including but not limited to: 1, abdominal bleeding; 2, gastrointestinal bleeding; 3, intestinal obstruction; 4, digestive tract leakage 5, anastomotic stenosis / gastric stenosis; 6, death ,etc. Visit 1: Baseline Visit (Day 0-1) Visit 2: Post-op 3 days Visit Visit 3: Post-op 7 days Visit Visit 4: Post-op 1 month Visit(±3 Days) Visit 5: Post-op 3 months Visit(±7 Days) Visit 6: Post-op 12 months Visit(±7 Days)
The extent of upper gastrointestinal symptoms after surgery1 year after surgeryWe use three scales to evaluate the incidence of upper gastrointestinal symptoms,include the Chinese translation of R-INVR(the Index of Nausea, Vomiting, and Retching)、EAT-10(Validity and Reliability of the Eating Assessment Tool) and GIS(GERD impact serve).These three scales quantify the degree of vomiting, difficulty swallowing, acid reflux, heartburn, etc.We will calculate the extent of the above upper gastrointestinal symptoms at five time points in one year after surgery. Visit 1: Post-op 3 days Visit Visit 2: Post-op 7 days Visit Visit 3: Post-op 1 month Visit(±3 Days) Visit 4: Post-op 3 months Visit(±7 Days) Visit 5: Post-op 12 months Visit(±7 Days)

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026